ArticleOncotarget2018

Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma.

Kwang Hyun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.